Drug Development

U.S. company to test use of obesity/smoking pill for heart disease

Published in Cancer Weekly, December 7th, 2004

Not content with having a drug that might merely fight obesity and smoking, the company developing this eagerly anticipated pill will soon launch studies to see if it can treat and prevent clogged arteries and heart disease.

The reason the drug looks promising is that even the one-third of people who didn't lose weight on rimonabant, or Acomplia, still had improvements in cholesterol and other heart-disease risk factors, said Douglas Greene, MD, vice president for corporate and regulatory affairs for Sanofi-Aventis, the French company developing the drug.

He also gave the first details on its safety and side effects, including the one major concern...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-12-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry